Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree with your opinion
Go AMBS
AMBS. Thanks to Blackhawk for keeping everyone in check only his opinion matters here. Or else you will be quoted to death.
Onward and beyond people
Go AMBS!
form the subsidiary and license the Company’s diagnostic IP to it, including the LymPro Alzheimer’s disease blood test, and the NuroPro Diagnostic Platform, including the NuroPro Parkinson’s disease blood test.
http://ir.stockpr.com/amarantus/all-sec-filings#document-6863-0001144204-13-007286
AMBS will still be compensated through the licensing fee.. how much will that fee (%) be we do not know..
that's my opinion.. they do not need to sell off.. they own them at a level this stock won't see again
plus they still have another note convertible at .10 cents meaning they feel the PPS will rise passed that again.
why sell and buy back higher than what you own it for now?
they Hold in my Opinion.. IND applications will be filed soon PPS will rise sharply, then they will get some cash back. PPS will not feel it.
Funding via JV's and Grants will put this conversation in the rear view mirror.
"Amarantus has made tremendous progress since our initial investment last year. We believe in the assets and the direction of the Company, and are pleased we can contribute to the Company's future growth," added Mikhail Gurevich, Managing Partner, Dominion Capital, LLC.
These are comments from a Financing partner that believes in the company its working with.. and its Newly amended $2 Million note is convertible at .10 Cents
Although they can sell their shares now at .08,,,,I highly doubt they would knowing what is in the works in the coming days..
they have very little risk since they own the shares at a great discount. I repeat NO Diluting... profit taking yes. but i am certain they will retain most of the shares...
AMBS is doing things the correct way.
the Company has retired a series of convertible notes with toxic financing terms that were issued between June 30, 2013 and November 1, 2013.
As a result of these transactions, the Company has eliminated the costly potential default and reset provisions associated with the Old Notes and Warrants that the Company believes were a potential impediment to future growth and more favorable future financing alternatives. With the retirement of the Old Notes and repurchase by the Company of the Warrants, the Company is no longer in default of any convertible notes or warrants, and has eliminated the risk of the further dilutive potential of resets and default provisions contained within those retired instruments. The company believes that this has streamlined and enhanced its capitalization structure placing the Company in a better positioned to move forward with the execution of its scientific advancement plan.
http://ir.stockpr.com/amarantus/all-sec-filings#document-6843-0001144204-13-006852
MANF: has potent curative properties that stops/or reverses the
progression of PD; improves behavior, the fundamental treatment goal of PD therapeutics;
The acquisition of Neurodegenerative Diagnostic’s intellectual property has also significantly
leveraged Amarantus. In this transaction Amarantus took ownership of 20 pending patent
applications covering a variety of biomarkers and assays related to the treatment of various
neurological disorders including Parkinson's, Alzheimer's, and ALS, as well as patent applications
related to Breast Cancer, neuromuscular disease and Chronic Myelogenous Leukemia. These
technologies provide an invaluable addition to Amarantus’ intellectual property estate, which
integrates seamlessly with and supports the company’s therapeutic platform.
Amarantus is currently preparing Phase 2 clinical trials for the acquired NuroPro Parkinson’s
Disease blood test, which serves as a diagnostic for early detection of PD
no dilution..for AMBS try again somewhere else
bye
Prior financing terms. Everything is in order. That deal was made when stock pps was in trips. Good deal that gerald eliminated the toxic financing. And he is working on eliminating the illegal defamation of the company too. Berlin too. Great CEO here heading the company
Nah why sell now when they know what is coming. Your assumption is off IMO. Shows how short sighted some can be.
IND announcement/s will have everyone scurrying to cover.
Make sure u click cover.
New Data and Acquisition Yield Strong EOY, Promising Q1
The disease-modifying capacity of Amarantus BioScience’s lead therapeutic candidate, MANF,
has been significantly validated by recent pre-clinical studies demonstrating that MANF inhibits
neurological deterioration in Parkinson’s disease (PD). These findings corroborate the potential of
MANF as first-in-class curative therapy for PD, which is critically needed. Currently used
medications only alleviate patient symptoms and do not function to reverse or stop disease
progression.
Additionally, Amarantus has recently announced the acquisition of Neurodegenerative
Diagnostic’s intellectual property portfolio, which includes diagnostics for PD and ALS – further
positioning the company as an emerging player in the field of neurological disorders.
Identified by Amarantus’ proprietary bioengineering and drug discovery platform, MANF is a
biological protein that stabilizes the nervous system in the body and has been found to have a
striking ability to save neurons from cell death when disease conditions were presented. The
present studies described show that key clinical hallmarks in an animal model of PD are
significantly improved by MANF, but not by GDNF, a therapeutic protein currently in Phase II
clinical trials, once developed by Amgen and now in trials through MedGenesis Therapeutix.
Specifically, research performed at UCLA’s School of Medicine shows that MANF improves
behavioral deficits by approximately 50% four weeks post-treatment, with a 35% improvement
seen as early as two weeks post-treatment. In contrast, GDNF did not provide any improvement in
behavioral deficits at any time point assayed. In a separate study performed at Neuroscience
Associates, MANF was shown to actually increase the density of neurons in the brain by
approximately 14%, whereas GDNF treatment showed no benefits in maintaining neuron density.
Finally, a third study performed at PharmaNet shows that MANF treatment produces a 100%
increase in dopamine concentration within the brain. Dopamine is a neurotransmitter produced in
the brain that is required for neurological health, and decreased dopamine is a major etiological
factor underlying PD and a primary target for therapeutic stabilization. GDNF was found to have
no effect on dopamine concentration in the brain.
Collectively, these data show that MANF: has potent curative properties that stops/or reverses the
progression of PD; improves behavior, the fundamental treatment goal of PD therapeutics;
increases the density of neurons in the brain, which are significantly decreased in PD; and
increases the concentration of dopamine in the brain, which decreases in PD and serves a major
etiological factor underlying the disease.
The acquisition of Neurodegenerative Diagnostic’s intellectual property has also significantly
leveraged Amarantus. In this transaction Amarantus took ownership of 20 pending patent
applications covering a variety of biomarkers and assays related to the treatment of various
neurological disorders including Parkinson's, Alzheimer's, and ALS, as well as patent applications
related to Breast Cancer, neuromuscular disease and Chronic Myelogenous Leukemia. These
technologies provide an invaluable addition to Amarantus’ intellectual property estate, which
integrates seamlessly with and supports the company’s therapeutic platform.
Amarantus is currently preparing Phase 2 clinical trials for the acquired NuroPro Parkinson’s
Disease blood test, which serves as a diagnostic for early detection of PD
http://ir.stockpr.com/amarantus/company-news/detail/563/onemedplace-research-releases-update-to-research-report-on-amarantus-bioscience
HEAVY SHORTING OF BMSN...SQUEEZE COMING
http://otcshortreport.com/BMSN
$$$$$$$$$$$
BARCHART = STRONG BUY for BMSN!!!!!!
www.barchart.com/quotes/stocks/BMSN
i think those estimates are very conservative...
I my self would want to take that blood test to check for possible future complications..
Our Chief Scientific Officer, Dr. John Commissiong,presented the data at the OneMedForum 2013 Healthcare Conference * RECENTLY UPDATED , and showed a significant positive impact in every data category, thus supporting advancing MANF in both Investigational New Drug (“IND”)- enabling studies and human clinical studies.
http://www.thechairmansblog.com/gerald-commissiong/2013-01/onwards-and-upwards-building-value-from-a-solid-foundation.html
The Company is now preparing to initiate IND-enabling studies."
The Company has retained a Swiss neuroscience-focused consulting firm to conduct a full audit of the data derived from these experiments and assist the Company in planning for its IND package.
http://ir.stockpr.com/amarantus/company-news/detail/553/amarantus-bioscience-reports-statistical-significance-achieved-for-manf-striatal-reinnervation-in-neurorestoration-animal-model-of-parkinsons-disease
Like i said SOON
Amarantus BioScience Secures an Additional $1.4 Million in Financing Commitments
SUNNYVALE, Calif., Jan. 31, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced it has secured an additional $1.4 million of financing commitments through an amendment of the initial Convertible Note with Dominion Capital. The original $600,000 note, dated November 14, 2012, was amended to a face value of $2,000,000 before deducting placement agent fees and other offering expenses. Proceeds will be used to provide funding for Amarantus' lead asset Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"), the advancement of the Company's diagnostic platforms, and for general working capital.
"With our recently reported positive efficacy data on MANF, and our newly acquired diagnostic platforms, this additional funding positions Amarantus to advance these assets for the potential treatment and diagnosis of Parkinson's disease and other apoptosis-related disorders," said Gerald E. Commissiong, President and CEO of Amarantus. "This also provides us the opportunity to explore additional indications where our product candidates may be beneficial."
In November 2012, Amarantus issued a Convertible Promissory Note to Dominion Capital, LLC in the principal amount of $600,000. On January 28, 2013, the note was amended to increase the principal amount of the note to $2,000,000. The Note bears interest at the rate of ten percent (10%) per annum, is convertible into common stock at $0.10 per share, and is pre-payable at the company's option at any time. The financing commitments will be realized by Amarantus under the note in six separate tranches of $200,000 to $250,000, subject to certain milestone achievements. Dominion has agreed to a "no shorting" provision.
"Amarantus has made tremendous progress since our initial investment last year. We believe in the assets and the direction of the Company, and are pleased we can contribute to the Company's future growth," added Mikhail Gurevich, Managing Partner, Dominion Capital, LLC.
Yeah its in the same document that said AMBS is Presenting at tomorrows conference
MANF: has potent curative properties that stops/or reverses the
progression of PD; improves behavior, the fundamental treatment goal of PD therapeutics
read full review... in my previous post.. but this was the EYE OPENER
New Data and Acquisition Yield Strong EOY, Promising Q1
The disease-modifying capacity of Amarantus BioScience’s lead therapeutic candidate, MANF,
has been significantly validated by recent pre-clinical studies demonstrating that MANF inhibits
neurological deterioration in Parkinson’s disease (PD). These findings corroborate the potential of
MANF as first-in-class curative therapy for PD, which is critically needed. Currently used
medications only alleviate patient symptoms and do not function to reverse or stop disease
progression.
Additionally, Amarantus has recently announced the acquisition of Neurodegenerative
Diagnostic’s intellectual property portfolio, which includes diagnostics for PD and ALS – further
positioning the company as an emerging player in the field of neurological disorders.
Identified by Amarantus’ proprietary bioengineering and drug discovery platform, MANF is a
biological protein that stabilizes the nervous system in the body and has been found to have a
striking ability to save neurons from cell death when disease conditions were presented. The
present studies described show that key clinical hallmarks in an animal model of PD are
significantly improved by MANF, but not by GDNF, a therapeutic protein currently in Phase II
clinical trials, once developed by Amgen and now in trials through MedGenesis Therapeutix.
Specifically, research performed at UCLA’s School of Medicine shows that MANF improves
behavioral deficits by approximately 50% four weeks post-treatment, with a 35% improvement
seen as early as two weeks post-treatment. In contrast, GDNF did not provide any improvement in
behavioral deficits at any time point assayed. In a separate study performed at Neuroscience
Associates, MANF was shown to actually increase the density of neurons in the brain by
approximately 14%, whereas GDNF treatment showed no benefits in maintaining neuron density.
Finally, a third study performed at PharmaNet shows that MANF treatment produces a 100%
increase in dopamine concentration within the brain. Dopamine is a neurotransmitter produced in
the brain that is required for neurological health, and decreased dopamine is a major etiological
factor underlying PD and a primary target for therapeutic stabilization. GDNF was found to have
no effect on dopamine concentration in the brain.
Collectively, these data show that MANF: has potent curative properties that stops/or reverses the
progression of PD; improves behavior, the fundamental treatment goal of PD therapeutics;
increases the density of neurons in the brain, which are significantly decreased in PD; and
increases the concentration of dopamine in the brain, which decreases in PD and serves a major
etiological factor underlying the disease.
The acquisition of Neurodegenerative Diagnostic’s intellectual property has also significantly
leveraged Amarantus. In this transaction Amarantus took ownership of 20 pending patent
applications covering a variety of biomarkers and assays related to the treatment of various
neurological disorders including Parkinson's, Alzheimer's, and ALS, as well as patent applications
related to Breast Cancer, neuromuscular disease and Chronic Myelogenous Leukemia. These
technologies provide an invaluable addition to Amarantus’ intellectual property estate, which
integrates seamlessly with and supports the company’s therapeutic platform.
Amarantus is currently preparing Phase 2 clinical trials for the acquired NuroPro Parkinson’s
Disease blood test, which serves as a diagnostic for early detection of PD
http://ir.stockpr.com/amarantus/company-news/detail/563/onemedplace-research-releases-update-to-research-report-on-amarantus-bioscience
U.S. Department of Defense introduced Amarantus to Banyan Biomarkers
100 % LEGITIMACY HERE
The US Government does not supports Scams.. Know what you own!
http://www.drugdiscoverynews.com/index.php?newsarticle=5717
IND Applications to be Filed Soon:
Amarantus BioScience Secures an Additional $1.4 Million in Financing Commitments
SUNNYVALE, Calif., Jan. 31, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced it has secured an additional $1.4 million of financing commitments through an amendment of the initial Convertible Note with Dominion Capital. The original $600,000 note, dated November 14, 2012, was amended to a face value of $2,000,000 before deducting placement agent fees and other offering expenses. Proceeds will be used to provide funding for Amarantus' lead asset Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"), the advancement of the Company's diagnostic platforms, and for general working capital.
"With our recently reported positive efficacy data on MANF, and our newly acquired diagnostic platforms, this additional funding positions Amarantus to advance these assets for the potential treatment and diagnosis of Parkinson's disease and other apoptosis-related disorders," said Gerald E. Commissiong, President and CEO of Amarantus. "This also provides us the opportunity to explore additional indications where our product candidates may be beneficial."
In November 2012, Amarantus issued a Convertible Promissory Note to Dominion Capital, LLC in the principal amount of $600,000. On January 28, 2013, the note was amended to increase the principal amount of the note to $2,000,000. The Note bears interest at the rate of ten percent (10%) per annum, is convertible into common stock at $0.10 per share, and is pre-payable at the company's option at any time. The financing commitments will be realized by Amarantus under the note in six separate tranches of $200,000 to $250,000, subject to certain milestone achievements. Dominion has agreed to a "no shorting" provision.
"Amarantus has made tremendous progress since our initial investment last year. We believe in the assets and the direction of the Company, and are pleased we can contribute to the Company's future growth," added Mikhail Gurevich, Managing Partner, Dominion Capital, LLC.
A Cure for Parkinson's Disease
Watch this Video.. AMBS is on the road to LEGENDARY Status
BUYINS.NET Updates Amarantus BioSciences SqueezeTrigger Report
Last Time we saw this notice... we took a nice ride up....
http://ih.advfn.com/p.php?pid=nmona&article=56209644&symbol=AMBS
Yeah,, Dr. Rubinfeld Founded Amgen DD does play an important part of decisions to Invest
Dr. Rubinfeld is on the Board of Advisors of AMBS and Speaks in Public on their Behalf
He is so concerned he Bought more shares of AMBS himself..
See latest FORM 4
http://ir.stockpr.com/amarantus/all-sec-filings#document-6793-0001144204-13-005998
lets be Real.. nice try
VICTORY = AMBS
This Company impresses me each day more and more, The CEO is Top Notch.
The Board of Advisors so much experience and clout in the BioTech field.
AMBS will be around for years to come
LEGEND in the Making
a blockbuster drug $AMBS$
Dr. Rubinfeld will assist management in positioning the Company’s development programs for partnering, as well as provide guidance on MANF-based small molecule strategies with his extensive medicinal chemistry background.
“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson’s, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company’s new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug.”
Enough Said...
U.S. Department of Defense introduced Amarantus to Banyan Biomarkers
100 % LEGITIMACY HERE
http://www.drugdiscoverynews.com/index.php?newsarticle=5717
AMBS : Remember the people in the picture with Gerald & Dr. John at the bottom of this web page? its like pieces to a Beautiful puzzle $$$$$$ its all a plan.. and its in Motion.
http://www.arrayit.com/Microarray_Diagnostics/Parkinsons_Disease/parkinsons_disease.html
Dr. Katherine Tynan was at Vitra Bioscience, a venture-backed biotechnology tools company, where she managed a broad range of functional areas including marketing, business development, operations, finance, legal and IP and participated in raising over $15M in capital.
Dr. Essam Sheta, Director of Biochemistry of Power3 Medical Products Amarantus has retained the services of Dr. Essam Sheta, former CLIA Laboratory Director at Power3, to assist the Company in preparing the phase II validation study required to gain Clinical Laboratory Improvement Amendments (CLIA) certification. Upon CLIA certification, the Company intends to begin the commercial sale of the NuroPro Parkinson’s Disease Blood Test.
Dr. Schena is considered the foremost authority on micorarray technology. Applications
There are five major areas where protein arrays are being applied:
Diagnostics -
The detection of antigens and antibodies in blood samples; the profiling of sera to discover new disease biomarkers
advancing MANF in both Investigational New Drug (“IND”)- enabling studies and human clinical studies
read this impressive Info.. not your average penny stock here.. AMBS Has a plan and its in motion.. Best of all it has the patents on the "FIRST IN CLASS" Molecule called MANF the new standard!!!!
http://www.thechairmansblog.com/gerald-commissiong/2013-01/onwards-and-upwards-building-value-from-a-solid-foundation.html
BUYINS.NET Updates Amarantus BioSciences SqueezeTrigger Report
Last Time we saw this notice... we took a nice ride up....
http://ih.advfn.com/p.php?pid=nmona&article=56209644&symbol=AMBS
GDNF =$270 Million MANF is Better Molecule
http://www.redorbit.com/news/health/1112720090/amarantus-biosciences-announces-manf-demonstrates-superiority-over-gdnf-in-neurorestoration/
$550 Million? $750 Million?
And this is just for 1 indication ... which we have been told MANF has many applications..
IMO smile
BUYER PREPARE for realizing this may be the most undervalued company to invest in for 2013 the Inevitable upside is Incredible
Don't be swayed read the DD up above and see how LEGIT AMBS is and how well run & organized it has displayed.
Just Check the resumes of its board of advisors :
Dr. Joseph Rubinfeld
Corporate Advisor
Dr. Rubinfeld is one of the four original co-founders of Amgen. Dr. Rubinfeld co-founded Amgen after a 23 year career in a variety of senior scientific and operational positions at Bristol Myers Squibb. Dr. Rubinfeld served as a Senior Director at Cetus Corporation from 1987 to 1990 until co-founded SuperGen in 1991, and served as its President & CEO through 2003. Dr. Rubinfeld is credited with inventing Amoxicillin, biodegradeable detergent and polaroid film. Dr. Rubinfeld received his PhD in Chemistry from Columbia University.
Dr. Robert J. Zimmerman
Product Development Advisor
Dr. Zimmerman is currently a biopharmaceutical product development consultant in the Bay Area at Zimmerman Consulting. Prior to starting his company, Dr. Zimmerman held senior management positions at Signature BioScience, Inc. where he served as Chief Operating Officer and as President, overseeing all research and development activities. Previously, he served as Vice President of Biotechnology Research at Bayer Corporation, where he was responsible for the management of all biotechnology research activities within the Pharmaceutical Division. At Bayer, he managed five departments including molecular technologies, scientific informatics, cell and analytical biology, pharmacology and preclinical development. Prior to Bayer, he served in positions of increasing responsibility at Chiron Corporation. Dr. Zimmerman has been involved in the submission of dozens of Investigational New Drug applications to the U.S. Food & Drug Administration and other regulatory agencies in a variety of indications, as well as successful marketing applications including interleukin-2 (IL2) and beta-interferon. Dr. Zimmerman received a doctor of science degree in physiology and radiobiology from the Harvard School of Public Health. He also earned a M.S. in physiology from The Ohio State University and a B.S. from Denison University.
Dr. Mark Benedyk
Corporate Advisor
Dr. Benedyk, is currently a Managing Partner at Rila Partners LLC, a business and corporate development consultancy he founded earlier in his career. Among other things, in this role, he is a Strategic Advisory Board member to a clinical-stage neuropsychiatry specialty care company, is a Director at the Center for Drug Research and Development Ventures, Inc., and is on the Translational Medicine Advisory Board of the CNS Regenerative Medicine Foundation. Previously he was head of The Pfizer Incubator (TPI) where his duties included membership on the Board of Directors, a director seat on several TPI portfolio company boards, overseeing the TPI operations team, and reviewing investment opportunities in multiple technologies. Dr. Benedyk also held executive Business Development roles at Ascenta Therapeutics, Optimer Biotechnology, Aurora Biosciences (acquired by Vertex Pharmaceuticals), and Elan Pharmaceuticals. He received his Ph.D. in Developmental Genetics, from The Rockefeller University, his B.S. degrees in Microbiology and Botany from the University of Michigan, B.S., and received financial certifications from Stanford University’s Graduate School of Business, and the University of Virginia Darden School of Business.
Dr. Owen Garrick
Corporate Advisor
Dr. Garrick joins Amarantus with over 20 years of pharmaceutical and biotechnology experience. He currently serves as the Chief Operating Officer at Bridge Clinical Research and is President of the American Medical Association Foundation. Prior to that, he was Director of Corporate Strategy and Business Development at McKesson Corporation. Dr. Garrick was Executive Director and Co-Head of Mergers & Acquisitions at Novartis Pharmaceuticals where he oversaw company acquisitions, hybrid equity/license rights deals, mature product divestments and venture investments in biotechnology companies. Prior to Novartis, Dr. Garrick was an associate at Goldman Sachs in New York. Dr. Garrick received his MD from Yale School of Medicine and earned his MBA from Wharton School of Business. He holds an AB from Princeton University, where he has served on the national fund raising board.
Clinton Allen
Corporate Advisor
Mr. Allen has extensive experience in the biopharmaceutical space. He has held senior leadership positions at Bristol Myers Squibb as Senior Director of Corporate Compliance Audit, Director of Risk Management, Director of Product Development and Commercialization, Director of In-licensing and Business Development. Mr. Allen was a captain in the United States Army and received his master in in Environmental Management & Sciences from Tufts University.
Mr. Toi Cook
Corporate Advisor
Mr. Cook had an 11 year career in the NFL, playing for the New Orleans Saints, San Francisco 49ers and Carolina Panthers. Mr. Cook had an interception as a defensive back in the 1994Super Bowl championship for the San Francisco 49ers. Since retiring from the NFL, Mr. Cook has worked primarily in Sports and Entertainment. He was Executive Vice President in the Sports Division at the Gersh Agency in Los Angeles from 2004-2006. He is the principle at Toi Cook Management Group, LLC (TCMG), which has consulted for Broadband Sports, A2A Holdings and Dreier Sports. He is currently a plaintiff in a lawsuit of former NFL players against the NFL in relationship to concussions sustained while playing. He served as the Player Representative for the NFLPA for eight years when he was a player in the NFL. He was a football and baseball star at Stanford University, where he graduated in Communications after winning the College World Series in 1987.
2013 Presenting Public Companies at BIO CEO 2013
AMBS presenting
http://www.bio.org/events/conferences/bio-ceo-2013-presenting-companies#Public
Amarantus BioScience to Present at the 15th Annual BIO CEO & Investor Conference
SUNNYVALE, Calif., Feb. 8, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced that Gerald E. Commissiong, President and Chief Executive Officer will present a corporate update at the 15th Annual BIO CEO & Investor Conference hosted by the Biotechnology Industry Organization (BIO). The presentation will take place on Monday, February 11, 2013 at the Waldorf Astoria in New York, NY.
The presentation will be webcast and available in the IR Calendar section of the Company's website at www.amarantus.com
About Amarantus BioScience, Inc.
Amarantus BioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property and licenses for the diagnosis of Parkinson's disease and Alzheimer's disease. For further information please visit www.Amarantus.com.
That company would be foolish to sell their AMBS shares now.. they know where its going. so do you regardless of where you want it to go , you know it is going UP
the terms to that deal were agreed upon a long time ago when the PPS was in trips.. you know that don't leave that out.
Have a wonderful day.
AMBS Biotech Stock of 2013
AMBS = TRANSPARENCY & SHAREHOLDER VALUE 1ST PRIORITY
Very Glad to have accumulated so many shares.. I will continue to add and lock up that float some more.
ANOTHER FORM 4 also... CEO Buying more
Slowly accumulating... NICE SIGN
http://ir.stockpr.com/amarantus/all-sec-filings#document-6793-0001144204-13-005998
other stocks CEO's are selling we know what that means...
AMBS CEO is accumulating.. HE KNOWS THE VALUE OF HIS COMPANY IS RISING
BUYER PREPARE for realizing this may be the most undervalued company to invest in for 2013 the Inevitable upside is Incredible
Don't be swayed read the DD up above and see how LEGIT AMBS is and how well run & organized it has displayed.
Just Check the resumes of its board of advisors :
Dr. Joseph Rubinfeld
Corporate Advisor
Dr. Rubinfeld is one of the four original co-founders of Amgen. Dr. Rubinfeld co-founded Amgen after a 23 year career in a variety of senior scientific and operational positions at Bristol Myers Squibb. Dr. Rubinfeld served as a Senior Director at Cetus Corporation from 1987 to 1990 until co-founded SuperGen in 1991, and served as its President & CEO through 2003. Dr. Rubinfeld is credited with inventing Amoxicillin, biodegradeable detergent and polaroid film. Dr. Rubinfeld received his PhD in Chemistry from Columbia University.
Dr. Robert J. Zimmerman
Product Development Advisor
Dr. Zimmerman is currently a biopharmaceutical product development consultant in the Bay Area at Zimmerman Consulting. Prior to starting his company, Dr. Zimmerman held senior management positions at Signature BioScience, Inc. where he served as Chief Operating Officer and as President, overseeing all research and development activities. Previously, he served as Vice President of Biotechnology Research at Bayer Corporation, where he was responsible for the management of all biotechnology research activities within the Pharmaceutical Division. At Bayer, he managed five departments including molecular technologies, scientific informatics, cell and analytical biology, pharmacology and preclinical development. Prior to Bayer, he served in positions of increasing responsibility at Chiron Corporation. Dr. Zimmerman has been involved in the submission of dozens of Investigational New Drug applications to the U.S. Food & Drug Administration and other regulatory agencies in a variety of indications, as well as successful marketing applications including interleukin-2 (IL2) and beta-interferon. Dr. Zimmerman received a doctor of science degree in physiology and radiobiology from the Harvard School of Public Health. He also earned a M.S. in physiology from The Ohio State University and a B.S. from Denison University.
Dr. Mark Benedyk
Corporate Advisor
Dr. Benedyk, is currently a Managing Partner at Rila Partners LLC, a business and corporate development consultancy he founded earlier in his career. Among other things, in this role, he is a Strategic Advisory Board member to a clinical-stage neuropsychiatry specialty care company, is a Director at the Center for Drug Research and Development Ventures, Inc., and is on the Translational Medicine Advisory Board of the CNS Regenerative Medicine Foundation. Previously he was head of The Pfizer Incubator (TPI) where his duties included membership on the Board of Directors, a director seat on several TPI portfolio company boards, overseeing the TPI operations team, and reviewing investment opportunities in multiple technologies. Dr. Benedyk also held executive Business Development roles at Ascenta Therapeutics, Optimer Biotechnology, Aurora Biosciences (acquired by Vertex Pharmaceuticals), and Elan Pharmaceuticals. He received his Ph.D. in Developmental Genetics, from The Rockefeller University, his B.S. degrees in Microbiology and Botany from the University of Michigan, B.S., and received financial certifications from Stanford University’s Graduate School of Business, and the University of Virginia Darden School of Business.
Dr. Owen Garrick
Corporate Advisor
Dr. Garrick joins Amarantus with over 20 years of pharmaceutical and biotechnology experience. He currently serves as the Chief Operating Officer at Bridge Clinical Research and is President of the American Medical Association Foundation. Prior to that, he was Director of Corporate Strategy and Business Development at McKesson Corporation. Dr. Garrick was Executive Director and Co-Head of Mergers & Acquisitions at Novartis Pharmaceuticals where he oversaw company acquisitions, hybrid equity/license rights deals, mature product divestments and venture investments in biotechnology companies. Prior to Novartis, Dr. Garrick was an associate at Goldman Sachs in New York. Dr. Garrick received his MD from Yale School of Medicine and earned his MBA from Wharton School of Business. He holds an AB from Princeton University, where he has served on the national fund raising board.
Clinton Allen
Corporate Advisor
Mr. Allen has extensive experience in the biopharmaceutical space. He has held senior leadership positions at Bristol Myers Squibb as Senior Director of Corporate Compliance Audit, Director of Risk Management, Director of Product Development and Commercialization, Director of In-licensing and Business Development. Mr. Allen was a captain in the United States Army and received his master in in Environmental Management & Sciences from Tufts University.
Mr. Toi Cook
Corporate Advisor
Mr. Cook had an 11 year career in the NFL, playing for the New Orleans Saints, San Francisco 49ers and Carolina Panthers. Mr. Cook had an interception as a defensive back in the 1994Super Bowl championship for the San Francisco 49ers. Since retiring from the NFL, Mr. Cook has worked primarily in Sports and Entertainment. He was Executive Vice President in the Sports Division at the Gersh Agency in Los Angeles from 2004-2006. He is the principle at Toi Cook Management Group, LLC (TCMG), which has consulted for Broadband Sports, A2A Holdings and Dreier Sports. He is currently a plaintiff in a lawsuit of former NFL players against the NFL in relationship to concussions sustained while playing. He served as the Player Representative for the NFLPA for eight years when he was a player in the NFL. He was a football and baseball star at Stanford University, where he graduated in Communications after winning the College World Series in 1987.